Ventyx Biosciences (NASDAQ:VTYX) Issues Earnings Results, Beats Estimates By $0.13 EPS

Ventyx Biosciences (NASDAQ:VTYX) issued its quarterly earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.13, Zacks reports.

Ventyx Biosciences Trading Down 5.2 %

Shares of NASDAQ:VTYX traded down $0.08 during midday trading on Thursday, reaching $1.45. The company had a trading volume of 732,901 shares, compared to its average volume of 1,532,521. The company’s 50 day moving average price is $2.00 and its 200 day moving average price is $2.15. Ventyx Biosciences has a 52-week low of $1.44 and a 52-week high of $11.48. The stock has a market cap of $102.53 million, a P/E ratio of -0.61 and a beta of 0.52.

Analysts Set New Price Targets

A number of research firms recently commented on VTYX. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Insiders Place Their Bets

In other Ventyx Biosciences news, insider John Nuss sold 21,119 shares of Ventyx Biosciences stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $2.36, for a total transaction of $49,840.84. Following the transaction, the insider now directly owns 464,582 shares of the company’s stock, valued at approximately $1,096,413.52. This trade represents a 4.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Sheila Gujrathi bought 130,000 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $2.31 per share, with a total value of $300,300.00. Following the completion of the acquisition, the director now directly owns 130,000 shares in the company, valued at $300,300. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 18.18% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.